Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash & Equivalents (2020 - 2025)

Oncology Institute's Cash & Equivalents history spans 6 years, with the latest figure at $33.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 32.42% year-over-year to $33.6 million; the TTM value through Dec 2025 reached $33.6 million, down 32.42%, while the annual FY2025 figure was $33.6 million, 32.42% down from the prior year.
  • Cash & Equivalents reached $33.6 million in Q4 2025 per TOI's latest filing, up from $27.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $115.2 million in Q4 2021 to a low of $11.5 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $40.5 million, with a median of $33.5 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 1820.21% in 2021, then tumbled 87.84% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $115.2 million in 2021, then crashed by 87.84% to $14.0 million in 2022, then skyrocketed by 139.03% to $33.5 million in 2023, then soared by 48.32% to $49.7 million in 2024, then crashed by 32.42% to $33.6 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Cash & Equivalents are $33.6 million (Q4 2025), $27.7 million (Q3 2025), and $30.3 million (Q2 2025).